Search

Displaying results 6951 - 6960 of 10000 in total
  1. Pathway

    Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)-OH(15S)/14:0)

    smpdb.ca/view/SMP0127433
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine · Pyrophosphoric acid
  2. Pathway

    Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)-OH(15S)/16:0)

    smpdb.ca/view/SMP0127435
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine · Pyrophosphoric acid
  3. Pathway

    Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)-OH(15S)/20:0)

    smpdb.ca/view/SMP0127437
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine · Pyrophosphoric acid
  4. Pathway

    Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

    smpdb.ca/view/SMP0127546
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine · Pyrophosphoric acid
  5. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles;[L1452] thus, those who are allergic to [Asparaginase Escherichia coli] do … Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent.

  6. Drug

    Lapyrium

    go.drugbank.com/drugs/DB09376
    Approved

    Lapyrium is a quaternary ammonium cation used as a surfactant, antistatic agent, and biocide in various cosmetic products [A19426]. It is commonly found formulated as lapyrium chloride.

  7. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    [L2611] It is currently used as a pesticide, and not used in any FDA approved drug products. … [A32825] Pyrithione derivatives, such as [DB06815] and sodium pyrithione, are widely used as cosmetic preservatives and as anti-dandruff agents in shampoos.

    Mixtures: Polytar AF Shampoo
  8. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  9. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

    Synonyms: di-(4-hydroxy-3-coumarinyl)methaneCategories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates
  10. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … It is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates